Do analysts recommend ANEB or BKHA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, ANEB or BKHA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A Black Hawk Acquisition N/A N/A N/A N/A N/A

Is ANEB or BKHA more profitable?

Black Hawk Acquisition's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Anebulo Pharmaceuticals N/A -74.57% -68.96% Black Hawk Acquisition N/A N/A N/A

Do analysts rate ANEB or MREO?

Mereo BioPharma Group has a consensus price target of $3.25, indicating a potential upside of 1,022.63%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, analysts plainly believe Mereo BioPharma Group is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mereo BioPharma Group 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13

Which has higher earnings and valuation, ANEB or MREO?

Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A Mereo BioPharma Group N/A N/A -$41.88M -$0.04 N/A

Is ANEB or MREO more profitable?

Anebulo Pharmaceuticals' return on equity of -74.57% beat Mereo BioPharma Group's return on equity. Company Net Margins Return on Equity Return on Assets Anebulo Pharmaceuticals N/A -74.57% -68.96% Mereo BioPharma Group N/A -74.82% -64.28%

Do analysts rate ANEB or TCRT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, ANEB or TCRT?

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A Alaunos Therapeutics N/A N/A -$4.18M -$1.91 N/A

Is ANEB or TCRT more profitable?

Anebulo Pharmaceuticals' return on equity of -74.57% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anebulo Pharmaceuticals N/A -74.57% -68.96% Alaunos Therapeutics N/A -232.60% -158.99%

Do analysts rate MCRB or ANEB?

Seres Therapeutics presently has a consensus target price of $17.00, indicating a potential upside of 264.81%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Seres Therapeutics is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer ANEB or MGX?

Metagenomi has a consensus target price of $6.00, suggesting a potential upside of 395.87%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Metagenomi 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Anebulo Pharmaceuticals (ANEB) Competitors

$0.31 -0.02 (-5.24%)

As of 10:15 AM Eastern

Compare

ANEB vs. BKHA, MREO, TCRT, MCRB, and MGX

Should you buy Anebulo Pharmaceuticals stock or one of its competitors? Anebulo Pharmaceuticals's main competitors and comparable companies include Black Hawk Acquisition (BKHA), Mereo BioPharma Group (MREO), Alaunos Therapeutics (TCRT), Seres Therapeutics (MCRB), and Metagenomi (MGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Anebulo Pharmaceuticals compare to Black Hawk Acquisition?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Black Hawk Acquisition (NASDAQ:BKHA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Black Hawk Acquisition had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 1 mentions for Black Hawk Acquisition and 0 mentions for Anebulo Pharmaceuticals. Black Hawk Acquisition's average media sentiment score of 0.75 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Black Hawk Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
Black Hawk Acquisition	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Black Hawk Acquisition's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Black Hawk Acquisition	N/A	N/A	N/A

Anebulo Pharmaceuticals has a beta of -1.82, suggesting that its share price is 282% less volatile than the broader market. Comparatively, Black Hawk Acquisition has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market.

Summary

Black Hawk Acquisition beats Anebulo Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Mereo BioPharma Group?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Anebulo Pharmaceuticals' return on equity of -74.57% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Mereo BioPharma Group	N/A	-74.82%	-64.28%

Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
Mereo BioPharma Group	N/A	N/A	-$41.88M	-$0.04	N/A

28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Anebulo Pharmaceuticals has a beta of -1.82, meaning that its share price is 282% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

Mereo BioPharma Group has a consensus price target of $3.25, indicating a potential upside of 1,022.63%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, analysts plainly believe Mereo BioPharma Group is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

In the previous week, Mereo BioPharma Group had 4 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 4 mentions for Mereo BioPharma Group and 0 mentions for Anebulo Pharmaceuticals. Mereo BioPharma Group's average media sentiment score of 0.15 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
Mereo BioPharma Group	Neutral

Summary

Mereo BioPharma Group beats Anebulo Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Alaunos Therapeutics?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

In the previous week, Anebulo Pharmaceuticals' average media sentiment score of 0.00 equaled Alaunos Therapeutics'average media sentiment score.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
Alaunos Therapeutics	Neutral

Anebulo Pharmaceuticals has a beta of -1.82, suggesting that its share price is 282% less volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1, suggesting that its share price is 200% less volatile than the broader market.

28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$1.91	N/A

Anebulo Pharmaceuticals' return on equity of -74.57% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Alaunos Therapeutics	N/A	-232.60%	-158.99%

Summary

Anebulo Pharmaceuticals beats Alaunos Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Anebulo Pharmaceuticals has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Anebulo Pharmaceuticals' return on equity of -74.57% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Seres Therapeutics presently has a consensus target price of $17.00, indicating a potential upside of 264.81%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Seres Therapeutics is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Seres Therapeutics has higher revenue and earnings than Anebulo Pharmaceuticals. Seres Therapeutics is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	59.28	$5.70M	-$2.43	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

In the previous week, Seres Therapeutics had 5 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 5 mentions for Seres Therapeutics and 0 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 0.00 beat Seres Therapeutics' score of -0.80 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Seres Therapeutics	Negative
Anebulo Pharmaceuticals	Neutral

Seres Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.82, indicating that its stock price is 282% less volatile than the broader market.

Summary

Seres Therapeutics beats Anebulo Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Metagenomi?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

In the previous week, Metagenomi had 3 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 3 mentions for Metagenomi and 0 mentions for Anebulo Pharmaceuticals. Metagenomi's average media sentiment score of 0.36 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Metagenomi is being referred to more favorably in the news media.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
Metagenomi	Neutral

Metagenomi has a consensus target price of $6.00, suggesting a potential upside of 395.87%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Comparatively, 12.5% of Metagenomi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Anebulo Pharmaceuticals has a beta of -1.82, meaning that its share price is 282% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Anebulo Pharmaceuticals has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Metagenomi	-384.61%	-63.65%	-44.52%

Anebulo Pharmaceuticals has higher earnings, but lower revenue than Metagenomi. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
Metagenomi	$13.56M	3.37	-$87.87M	-$2.49	N/A

Summary

Metagenomi beats Anebulo Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Anebulo Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANEB vs. The Competition

Export

Metric	Anebulo Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.75M	$3.99B	$7.29B	$12.71B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-1.65	11.75	271.38	24.10
Price / Sales	N/A	1,398.77	638.95	90.12
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	1.12	17.26	11.18	6.40
Net Income	-$8.48M	-$22.72M	$3.46B	$348.28M
7 Day Performance	-25.55%	2.89%	1.98%	0.91%
1 Month Performance	4.23%	9.74%	7.32%	5.10%
1 Year Performance	-87.97%	54.81%	24.76%	16.16%

Anebulo Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANEB Anebulo Pharmaceuticals	N/A	$0.31 -5.2%	N/A	-87.3%	$12.75M	N/A	N/A	4	Gap Down
BKHA Black Hawk Acquisition	N/A	$11.89 +0.9%	N/A	+8.4%	$48.93M	N/A	N/A	N/A	Positive News
MREO Mereo BioPharma Group	3.4424 of 5 stars	$0.30 -0.9%	$3.25 +973.0%	-82.9%	$48.76M	$500K	N/A	40
TCRT Alaunos Therapeutics	0.7018 of 5 stars	$2.00 +1.5%	N/A	-0.6%	$48.11M	N/A	N/A	40	Positive News Gap Down
MCRB Seres Therapeutics	2.7692 of 5 stars	$4.72 +1.7%	$17.00 +260.2%	-76.5%	$46.13M	$790K	N/A	330

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANEB) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anebulo Pharmaceuticals (ANEB) Competitors

ANEB vs. BKHA, MREO, TCRT, MCRB, and MGX

How does Anebulo Pharmaceuticals compare to Black Hawk Acquisition?

Summary

How does Anebulo Pharmaceuticals compare to Mereo BioPharma Group?

Summary

How does Anebulo Pharmaceuticals compare to Alaunos Therapeutics?

Summary

How does Anebulo Pharmaceuticals compare to Seres Therapeutics?

Summary

How does Anebulo Pharmaceuticals compare to Metagenomi?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB vs. The Competition

Anebulo Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anebulo Pharmaceuticals (ANEB) Competitors

ANEB vs. BKHA, MREO, TCRT, MCRB, and MGX

How does Anebulo Pharmaceuticals compare to Black Hawk Acquisition?

Which has higher valuation & earnings, ANEB or BKHA?

Do institutionals and insiders hold more shares of ANEB or BKHA?

Does the media favor ANEB or BKHA?

Do analysts recommend ANEB or BKHA?

Is ANEB or BKHA more profitable?

Which has more risk & volatility, ANEB or BKHA?

Summary

How does Anebulo Pharmaceuticals compare to Mereo BioPharma Group?

Is ANEB or MREO more profitable?

Which has higher earnings and valuation, ANEB or MREO?

Do insiders & institutionals have more ownership in ANEB or MREO?

Which has more risk & volatility, ANEB or MREO?

Do analysts rate ANEB or MREO?

Does the media prefer ANEB or MREO?

Summary

How does Anebulo Pharmaceuticals compare to Alaunos Therapeutics?

Does the media refer more to ANEB or TCRT?

Which has more risk & volatility, ANEB or TCRT?

Do institutionals & insiders believe in ANEB or TCRT?

Do analysts rate ANEB or TCRT?

Which has preferable earnings & valuation, ANEB or TCRT?

Is ANEB or TCRT more profitable?

Summary

How does Anebulo Pharmaceuticals compare to Seres Therapeutics?

Is MCRB or ANEB more profitable?

Do insiders & institutionals have more ownership in MCRB or ANEB?

Do analysts rate MCRB or ANEB?

Which has higher earnings and valuation, MCRB or ANEB?

Does the media favor MCRB or ANEB?

Which has more volatility & risk, MCRB or ANEB?

Summary

How does Anebulo Pharmaceuticals compare to Metagenomi?

Does the media refer more to ANEB or MGX?

Do analysts prefer ANEB or MGX?

Do institutionals & insiders have more ownership in ANEB or MGX?

Which has more volatility & risk, ANEB or MGX?

Is ANEB or MGX more profitable?

Which has better valuation and earnings, ANEB or MGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB vs. The Competition

Anebulo Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools